The trend of staff redundancies and company down-sizing is prevalent in most if not all established life science ecosystems as reported in the recent “Biotech layoffs in 2025: The Labiotech tracker”. One Nucleus members are far from immune to this phenomenon being experienced of course and we see numerous examples of member employees finding themselves back in the jobs market. Mindful of the impact, One Nucleus strives to support both the redundant employees and the companies in the unfortunate position to be laying people off in order to maximise the chances of redeployment.…
Asymchem has announced a significant expansion of its flow chemistry capabilities at its Sandwich, UK facility.
SANDWICH, UNITED KINGDOM, August 2025 - Asymchem, a global leader in contract development and manufacturing (CDMO) solutions, has announced a significant expansion of its flow chemistry capabilities at Discovery Park, in Sandwich, UK. This milestone marks the first deployment of Asymchem’s proprietary and CE marking flow equipment in the Western market that further strengthens the company’s position in the adoption of advanced flow chemistry technologies.
The newly commissioned…
The August edition of our People Pathways newsletter is now available to read here!
Featuring:✅ One Nucleus upcoming courses✅ New Training Opportunities - We would love to hear from you on this!✅ Building Networks, Supporting Careers: Insights from Our AugustRoundtables✅ A One Nucleus Skills Exchange Forum on WhatsApp – Seeking Opinion✅ Details on the University of Cambridge Life Sciences Fair 2025✅ Cogent Skills Enabling Businesses to Take on Apprentices in Uncertain Times
Qureight’s advanced AI 3D imaging platform to be used across clinical trial to evaluate anatomical lung changes in adult patients, including during patient enrolment
CAL101 is a first-in-class monoclonal antibody that neutralises the S100A4 protein, which is an upstream driver and amplifier of the multiple pro-fibrotic pathways active in IPF
Cambridge, UK, 27 August 2025 – Qureight, a techbio company advancing the understanding of lung and heart disease through application of its AI-powered imaging and clinical data curation platform, today announced that it has been selected by…
Sandwich, UK - 26 August 2025: Discovery Park, Kent’s leading hub for science and technology, today announced the arrival of two pioneering biotech companies to its innovation campus. iLoF (Intelligent Lab on Fiber), a digital health company and MilaK, a precision fermentation protein business, have now moved into their new laboratory space in Sandwich, Kent.
iLoF is on a mission to accelerate personalised drug development, by optimising clinical and pre-clinical drug development, beginning with a key focus on Alzheimer’s Disease. This impressive digital health company is leveraging…
Medicilon is pleased to announce the addition of comprehensive NAM (New Approach Methodologies) support to its drug R&D service platform. This is in line with the FDA's recent decision to undertake a phased-out approach to animal testing requirement for monoclonal antibodies and other biologic drugs, replacing it with in vitro models and technology. This decision officially incorporates NAMs, such as AI and organoids, into mainstream drug safety and efficacy assessment.
NAMs, including AI-driven simulations and advanced in vitro models, are transforming drug discovery and…
Creative Biolabs has recently made upgrades to its CAR-T preclinical research, further enhancing the safety and functional evaluation of these therapies.The upward curve in cell and gene therapies means CAR-T remains front-page science for its promise across cancers and other hard-to-treat conditions. However, rigorous in vivo validation and safety assessment are still the guards against translating research enthusiasm into real-world risk. Creative Biolabs pledges a one-stop preclinical lift for CAR-T candidates, leaning on years of building and operating the CAR-T animal models. …
Devens, MA, USA — Veranova, a global leader in the development and manufacture of specialty and complex active pharmaceutical ingredients (API) for the pharmaceutical and biotech sectors, announced today that a routine current Good Manufacturing Practice (cGMP) surveillance inspection of Veranova’s Devens, Massachusetts site, completed by the Food and Drug Administration (FDA) New England District on July 31, 2025, concluded without any Form 483s and with a “No Action Indicated” (NAI) classification. This result demonstrates Veranova’s commitment to driving the highest standards of…
In an era when precision is paramount, the latest research published in Nature Reviews Drug Discovery has reignited conversations around the need for ultra-high-quality antibody libraries in drug development."The study underscores the pivotal role of precise molecular targeting—especially antibodies—in decoding the complexities of protein functions and advancing therapeutic strategies for intractable diseases." A scientist from Creative Biolabs says, which is a biotechnology solution provider playing a key role nowadays offering high-performance antibody discovery platforms to accelerate the…
Oxford, United Kingdom – 6th August 2025 – OMass Therapeutics (‘OMass’ or ‘the Company’), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, today announces the appointment of Carol A. Schafer as non-executive Director and Chair of the Audit Committee. Carol has more than 25 years of experience in investment banking, equity capital markets, corporate finance and business development in the healthcare sector. She currently serves on the Board of Directors for Insmed Incorporated (Nasdaq: INSM),…